Literature DB >> 11269973

Antineutrophil cytoplasmic antibodies (ANCAs) in patients with inflammatory bowel disease show no correlation with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme: a Singapore study.

C J Ooi1, B L Lim, W K Cheong, A E Ling, H S Ng.   

Abstract

INTRODUCTION: The pathogenic importance of antineutrophil cytoplasmic antibodies (ANCAs) in inflammatory bowel disease (IBD) is unclear and target antigen localisation studies may lend insight to the specific pathogenic mechanisms of IBD. In this pilot study, we looked at occurrence of ANCA in Asian IBD patients. In ANCA-positive samples, we analysed for the presence of target antigens i.e. proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme.
MATERIALS AND METHODS: This prospective study was carried out from July 1997 to February 1998. Sera were screened for ANCAs with indirect immunofluorescent test and tested with an enzyme immunoassay (ELISA) kit which provides a semi-quantitative assay for human IgG autoantibodies against 6 antigens: proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme.
RESULTS: A total of 75 patients were studied: 50 with IBD and 25 controls with functional bowel disease. Ten had Crohn's disease (CD) and 40 had ulcerative colitis (UC). There was no racial predilection among the Chinese, Malays or Indians. In CD, 1 was positive for cytoplasmic ANCA (cANCA) and 2 for perinuclear ANCA (pANCA). In UC, 4 were positive for pANCA, 15 for atypical perinuclear ANCA (apANCA) and 1 for cANCA. In the CD and UC population, the proportion positive for ANCA was 30% and 50%, respectively. There was no ANCA detected among the controls. Of those ANCA-positive IBD patients (n:23), only 1 demonstrated anti-myeloperoxidase antibodies. No antibodies were detected against the other 5 antigens tested.
CONCLUSIONS: This pilot Singapore study concludes that there is no significant ANCA association with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11269973

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  6 in total

Review 1.  Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.

Authors:  Mona Abdel-Tawab; Oliver Werz; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

Review 2.  Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

3.  High Prevalence of Neutrophil Cytoplasmic Autoantibodies in Infants with Food Protein-Induced Proctitis/Proctocolitis: Autoimmunity Involvement?

Authors:  Alena Sekerkova; Martin Fuchs; Eva Cecrdlova; Veronika Svachova; Ivana Kralova Lesna; Ilja Striz; Helena Tlaskalova-Hogenova
Journal:  J Immunol Res       Date:  2015-09-21       Impact factor: 4.818

4.  PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).

Authors:  Laura M Stinton; Chelsea Bentow; Michael Mahler; Gary L Norman; Bertus Eksteen; Andrew L Mason; Gilaad G Kaplan; Bjorn Lindkvist; Gideon M Hirschfield; Piotr Milkiewicz; Angela Cheung; Harry L A Janssen; Marvin J Fritzler
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 5.  Antineutrophil cytoplasmic antibodies (ANCA) - their role in pathogenesis, diagnosis, and treatment monitoring of ANCA-associated vasculitis.

Authors:  Justyna FijoŁek; ElŻbieta Wiatr
Journal:  Cent Eur J Immunol       Date:  2020-07-09       Impact factor: 2.085

Review 6.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.